| Diffuse Large B-Cell Lymphoma
Adcetris vs Monjuvi
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Adcetris vs Monjuvi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMonjuvi has a higher rate of injection site reactions vs Adcetris based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Monjuvi but not Adcetris, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adcetris
Monjuvi
At A Glance
IV infusion
Every 2-3 weeks
CD30-directed antibody-drug conjugate
IV infusion
Every 2 weeks
CD19-directed monoclonal antibody
Indications
- Hodgkin Disease
- Angioimmunoblastic Lymphadenopathy
- Peripheral T-Cell Lymphoma
- Mycosis Fungoides
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Dosing
Hodgkin Disease (previously untreated Stage III/IV, adults) 1.2 mg/kg (max 120 mg) IV in combination with chemotherapy every 2 weeks for a maximum of 12 doses.
Hodgkin Disease (previously untreated high risk, pediatric) 1.8 mg/kg (max 180 mg) IV in combination with chemotherapy every 3 weeks for a maximum of 5 doses.
Hodgkin Disease (post-auto-HSCT consolidation) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.
Hodgkin Disease (relapsed) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.
Peripheral T-Cell Lymphoma, Angioimmunoblastic Lymphadenopathy (previously untreated) 1.8 mg/kg (max 180 mg) IV in combination with cyclophosphamide, doxorubicin, and prednisone every 3 weeks for 6 to 8 doses.
Peripheral T-Cell Lymphoma (relapsed systemic ALCL) 1.8 mg/kg (max 180 mg) IV every 3 weeks until disease progression or unacceptable toxicity.
Mycosis Fungoides (relapsed pcALCL or CD30-expressing) 1.8 mg/kg (max 180 mg) IV every 3 weeks for a maximum of 16 cycles.
Diffuse Large B-Cell Lymphoma (relapsed or refractory) 1.2 mg/kg (max 120 mg) IV in combination with lenalidomide and a rituximab product every 3 weeks until disease progression or unacceptable toxicity.
Diffuse Large B-Cell Lymphoma 12 mg/kg IV; Cycle 1: Days 1, 4, 8, 15, and 22; Cycles 2-3: Days 1, 8, 15, and 22; Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle; in combination with lenalidomide for up to 12 cycles, then MONJUVI as monotherapy until disease progression or unacceptable toxicity.
Contraindications
- Concomitant use with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation)
—
Adverse Reactions
Most common (>=20%) Peripheral neuropathy, fatigue, nausea, diarrhea, musculoskeletal pain, pyrexia, rash, upper respiratory tract infection, constipation, alopecia
Serious Febrile neutropenia, pneumonia, hepatotoxicity, peripheral motor neuropathy, pulmonary toxicity, progressive multifocal leukoencephalopathy, tumor lysis syndrome, serious and opportunistic infections
Postmarketing Febrile neutropenia, acute pancreatitis, gastrointestinal complications, hepatotoxicity, progressive multifocal leukoencephalopathy, serious and opportunistic infections, hyperglycemia, noninfectious pulmonary toxicity including pneumonitis and ARDS, toxic epidermal necrolysis
Most common (>=20%) Neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, decreased appetite
Serious Infections (including pneumonia, febrile neutropenia), cerebrovascular accident, respiratory failure, progressive multifocal leukoencephalopathy, sudden death
Pharmacology
Brentuximab vedotin is a CD30-directed antibody-drug conjugate (ADC) consisting of a chimeric IgG1 anti-CD30 antibody linked to MMAE, a microtubule-disrupting agent; upon binding to CD30-expressing tumor cells the ADC is internalized and MMAE is released via proteolytic cleavage, disrupting the microtubule network within the cell and inducing cell cycle arrest and apoptosis.
Tafasitamab-cxix is an Fc-modified CD19-directed monoclonal antibody that mediates B-cell lysis through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP); in combination with lenalidomide, it demonstrates increased ADCC activity in DLBCL tumor cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adcetris
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Monjuvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Adcetris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Monjuvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Adcetris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Monjuvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Adcetris Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdcetrisView full Adcetris profile
MonjuviView full Monjuvi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.